Schistosomiasis - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Schistosomiasis - Pipeline Review, H1 2016', provides an overview of the Schistosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Schistosomiasis - The report reviews pipeline therapeutics for Schistosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Schistosomiasis therapeutics and enlists all their major and minor projects - The report assesses Schistosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Schistosomiasis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Schistosomiasis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Schistosomiasis Overview 6 Therapeutics Development 7 Pipeline Products for Schistosomiasis - Overview 7 Pipeline Products for Schistosomiasis - Comparative Analysis 8 Schistosomiasis - Therapeutics under Development by Companies 9 Schistosomiasis - Therapeutics under Investigation by Universities/Institutes 10 Schistosomiasis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Schistosomiasis - Products under Development by Companies 13 Schistosomiasis - Products under Investigation by Universities/Institutes 14 Schistosomiasis - Companies Involved in Therapeutics Development 15 BioDiem Ltd 15 Concert Pharmaceuticals, Inc. 16 Kancera AB 17 LondonPharma Ltd 18 Merck KGaA 19 Schistosomiasis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 BDM-I - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 D-Praziquantel - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 intestinal schistosomiasis vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 intestinal schistosomiasis vaccine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 L-Praziquantel - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecule for Schistosomiasis - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule for Schistosomiasis - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Schistosomiasis - Recent Pipeline Updates 36 Schistosomiasis - Dormant Projects 38 Schistosomiasis - Product Development Milestones 39 Featured News & Press Releases 39 Aug 23, 2013: BioDiem US patent for skin and wound infections 39 Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites 39 Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I 39 Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I 40 Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Schistosomiasis, H1 2016 7 Number of Products under Development for Schistosomiasis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Schistosomiasis - Pipeline by BioDiem Ltd, H1 2016 15 Schistosomiasis - Pipeline by Concert Pharmaceuticals, Inc., H1 2016 16 Schistosomiasis - Pipeline by Kancera AB, H1 2016 17 Schistosomiasis - Pipeline by LondonPharma Ltd, H1 2016 18 Schistosomiasis - Pipeline by Merck KGaA, H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Schistosomiasis Therapeutics - Recent Pipeline Updates, H1 2016 36 Schistosomiasis - Dormant Projects, H1 2016 38
List of Figures
Number of Products under Development for Schistosomiasis, H1 2016 7 Number of Products under Development for Schistosomiasis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.